Kymera Therapeutics · 16 hours ago
Associate Director, Statistical Programming
Greater Boston
Full-time
Hybrid
Lead/Staff, Director/Executive
$160K/yr - $240K/yr
8+ years expKymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation to develop innovative therapies. They are seeking an experienced Associate Director of Statistical Programming to lead programming efforts across multiple clinical studies, ensuring high-quality, timely, and compliant statistical deliverables in support of their pipeline.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Lead across multiple studies or a clinical program, ensuring timely, accurate, and regulatory-compliant deliverables, including oversight of SDTM, ADaM, and TLF deliverables by vendors
Collaborate closely with internal study team and external partners to ensure alignment on timelines, priorities, and quality expectations
Oversee CRO deliverables as needed, with a focus on technical quality and consistency, ensuring clear documentation of the process
Develop, validate, and maintain datasets (SDTM, ADaM), tables, listings, and figures, TLFs) in accordance with regulatory guidelines and internal standards to assist with data review, CSR, annual data report, publication, in-house data request, etc
Provide expertise in statistical programming for regulatory submissions (e.g., FDA, EMA), including electronic submission standards (eCTD)
Coordinate and schedule data transfers and delivery of required outputs as the lead or support programmer on studies
Review key clinical study or program documents
Manage multiple tasks, troubleshoot technical and project issues, and assist with the infrastructure development of the department; Evaluate and implement innovative tools and programming technologies to streamline processes and improve team efficiency and quality
Stay current with industry trends, best practices, and emerging technologies in statistical programming and data analysis
Additional duties and responsibilities as required
Qualification
Required
MS or equivalent degree in Statistics, Biostatistics, Computer Science, or related field
8+ years of statistical programming experience in the pharmaceutical or biotechnology industry, including experience supporting late-phase (Phase II and III) clinical trials
Proven experience overseeing CROs and external vendors, with accountability for quality, timelines, and deliverables
Deep, hands-on expertise with CDISC standards (SDTM, ADaM) and strong knowledge of regulatory submission requirements (e.g., NDA/MAA)
Proven ability to independently produce high-quality analysis datasets, tables, listings, and figures for data request
Strong expertise in programming and analyzing efficacy endpoints, with the ability to efficiently translate clinical objectives into analysis-ready datasets and outputs
Demonstrated ability to collaborate effectively in cross-functional settings and manage competing priorities in a fast-paced or startup environment
Proactive, solutions-oriented mindset with excellent communication and leadership skills
Preferred
R or Python is plus
Benefits
Eligibility for annual bonus
Equity participation
Comprehensive benefits
Company
Kymera Therapeutics
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
51-200 employees
H1B Sponsorship
Kymera Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (5)
2024 (2)
2023 (4)
2022 (3)
2021 (3)
Funding
Current Stage
Public CompanyTotal Funding
$1.96BKey Investors
Biotechnology Value FundAtlas Venture
2025-12-10Post Ipo Equity· $602M
2025-06-26Post Ipo Equity· $250.8M
2024-08-19Post Ipo Equity· $225M
Leadership Team
Nello Mainolfi
Founder, President and Chief Executive Officer
Jeremy Chadwick
Chief Operating Officer
Recent News
2026-01-16
2026-01-11
Company data provided by crunchbase